Potential Hematopoietic Effects of SGLT2 Inhibitors in Patients with Cardiac Amyloidosis
Background: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have been found to have potential hematopoietic effects in patients with heart failure (HF). However, these benefits have not been studied in patients with cardiac amyloidosis (CA). CA patients present with HF symptoms...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IMR Press
2025-03-01
|
| Series: | Reviews in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.imrpress.com/journal/RCM/26/3/10.31083/RCM26081 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850067613093199872 |
|---|---|
| author | Nikita Ermolaev Robin Willixhofer Christoph Krall Christina Kronberger René Rettl Christina Binder Franz Duca Christian Nitsche Andreas Kammerlander Michael Poledniczek Bernhard Gregshammer Diana Ahmadi-Fazel Mahshid Eslami Luciana Camuz Ligios Johannes Kastner Jutta Bergler-Klein Roza Badr Eslam |
| author_facet | Nikita Ermolaev Robin Willixhofer Christoph Krall Christina Kronberger René Rettl Christina Binder Franz Duca Christian Nitsche Andreas Kammerlander Michael Poledniczek Bernhard Gregshammer Diana Ahmadi-Fazel Mahshid Eslami Luciana Camuz Ligios Johannes Kastner Jutta Bergler-Klein Roza Badr Eslam |
| author_sort | Nikita Ermolaev |
| collection | DOAJ |
| description | Background: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have been found to have potential hematopoietic effects in patients with heart failure (HF). However, these benefits have not been studied in patients with cardiac amyloidosis (CA). CA patients present with HF symptoms and often suffer from iron deficiency, which has a negative impact on erythropoiesis and leads to lower hemoglobin and hematocrit levels. We sought to determine the potential effects of SGLT2i on hematological parameters and functional capacity (FC) in CA patients. Methods: A prospective analysis was conducted to compare the effects of SGLT2i in patients who received the best medical therapy (BMT) along with SGLT2i (n = 20), versus patients receiving only BMT without SGLT2i (n = 20) (historical control group). All patients underwent blood testing and cardiopulmonary exercise testing (CPET) at baseline (BL) and after 6 months [interquartile range (IQR): 4.0 to 8.0]. Results: The SGLT2i-based therapy resulted in a significant improvement and difference in hematological parameters at 6 months follow-up compared to the control group. In the SGLT2i group, the mean hemoglobin level increased (+1.2 mg/dL), whereas in the control group, it decreased (–0.8 g/dL) (p < 0.001 for overall group comparison). The hematocrit showed a significant increase in the SGLT2i group (+4.4%) compared to a decrease in the control group (–1.8%) (p < 0.001). Additionally, the serum iron level improved in the SGLT2i-treated group (+ 5.5 [–5.0 to 17.5] μg/dL vs. –6.0 [–15.0 to 4.0] μg/dL, p = 0.121). Although there was no significant change in the peak oxygen consumption (peak VO2, (mL/min)/kg) (p = 0.206), as well as in pulmonary ventilation (VE)/carbon dioxide production (VCO2) slope in both groups (p = 0.964), the SGLT2i group maintained a peak VO2 and VE/VCO2 slope throughout the study. Conclusions: SGLT2i therapy improved hematological parameters and stabilized the FC of CA patients. |
| format | Article |
| id | doaj-art-18cdf8396c4d4fcaa0e46a01ea2fc32d |
| institution | DOAJ |
| issn | 1530-6550 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | IMR Press |
| record_format | Article |
| series | Reviews in Cardiovascular Medicine |
| spelling | doaj-art-18cdf8396c4d4fcaa0e46a01ea2fc32d2025-08-20T02:48:16ZengIMR PressReviews in Cardiovascular Medicine1530-65502025-03-012632608110.31083/RCM26081S1530-6550(24)01711-3Potential Hematopoietic Effects of SGLT2 Inhibitors in Patients with Cardiac AmyloidosisNikita Ermolaev0Robin Willixhofer1Christoph Krall2Christina Kronberger3René Rettl4Christina Binder5Franz Duca6Christian Nitsche7Andreas Kammerlander8Michael Poledniczek9Bernhard Gregshammer10Diana Ahmadi-Fazel11Mahshid Eslami12Luciana Camuz Ligios13Johannes Kastner14Jutta Bergler-Klein15Roza Badr Eslam16Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, AustriaDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, AustriaCenter for Medical Data Science, Medical University of Vienna, 1090 Vienna, AustriaDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, AustriaDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, AustriaDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, AustriaDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, AustriaDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, AustriaDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, AustriaDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, AustriaDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, AustriaDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, AustriaDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, AustriaDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, AustriaDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, AustriaDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, AustriaDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, AustriaBackground: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have been found to have potential hematopoietic effects in patients with heart failure (HF). However, these benefits have not been studied in patients with cardiac amyloidosis (CA). CA patients present with HF symptoms and often suffer from iron deficiency, which has a negative impact on erythropoiesis and leads to lower hemoglobin and hematocrit levels. We sought to determine the potential effects of SGLT2i on hematological parameters and functional capacity (FC) in CA patients. Methods: A prospective analysis was conducted to compare the effects of SGLT2i in patients who received the best medical therapy (BMT) along with SGLT2i (n = 20), versus patients receiving only BMT without SGLT2i (n = 20) (historical control group). All patients underwent blood testing and cardiopulmonary exercise testing (CPET) at baseline (BL) and after 6 months [interquartile range (IQR): 4.0 to 8.0]. Results: The SGLT2i-based therapy resulted in a significant improvement and difference in hematological parameters at 6 months follow-up compared to the control group. In the SGLT2i group, the mean hemoglobin level increased (+1.2 mg/dL), whereas in the control group, it decreased (–0.8 g/dL) (p < 0.001 for overall group comparison). The hematocrit showed a significant increase in the SGLT2i group (+4.4%) compared to a decrease in the control group (–1.8%) (p < 0.001). Additionally, the serum iron level improved in the SGLT2i-treated group (+ 5.5 [–5.0 to 17.5] μg/dL vs. –6.0 [–15.0 to 4.0] μg/dL, p = 0.121). Although there was no significant change in the peak oxygen consumption (peak VO2, (mL/min)/kg) (p = 0.206), as well as in pulmonary ventilation (VE)/carbon dioxide production (VCO2) slope in both groups (p = 0.964), the SGLT2i group maintained a peak VO2 and VE/VCO2 slope throughout the study. Conclusions: SGLT2i therapy improved hematological parameters and stabilized the FC of CA patients.https://www.imrpress.com/journal/RCM/26/3/10.31083/RCM26081amyloid cardiomyopathyheart failuresodium-glucose cotransporter 2 inhibitorshematopoiesisfunctional capacitycardiopulmonary exercise testing |
| spellingShingle | Nikita Ermolaev Robin Willixhofer Christoph Krall Christina Kronberger René Rettl Christina Binder Franz Duca Christian Nitsche Andreas Kammerlander Michael Poledniczek Bernhard Gregshammer Diana Ahmadi-Fazel Mahshid Eslami Luciana Camuz Ligios Johannes Kastner Jutta Bergler-Klein Roza Badr Eslam Potential Hematopoietic Effects of SGLT2 Inhibitors in Patients with Cardiac Amyloidosis Reviews in Cardiovascular Medicine amyloid cardiomyopathy heart failure sodium-glucose cotransporter 2 inhibitors hematopoiesis functional capacity cardiopulmonary exercise testing |
| title | Potential Hematopoietic Effects of SGLT2 Inhibitors in Patients with Cardiac Amyloidosis |
| title_full | Potential Hematopoietic Effects of SGLT2 Inhibitors in Patients with Cardiac Amyloidosis |
| title_fullStr | Potential Hematopoietic Effects of SGLT2 Inhibitors in Patients with Cardiac Amyloidosis |
| title_full_unstemmed | Potential Hematopoietic Effects of SGLT2 Inhibitors in Patients with Cardiac Amyloidosis |
| title_short | Potential Hematopoietic Effects of SGLT2 Inhibitors in Patients with Cardiac Amyloidosis |
| title_sort | potential hematopoietic effects of sglt2 inhibitors in patients with cardiac amyloidosis |
| topic | amyloid cardiomyopathy heart failure sodium-glucose cotransporter 2 inhibitors hematopoiesis functional capacity cardiopulmonary exercise testing |
| url | https://www.imrpress.com/journal/RCM/26/3/10.31083/RCM26081 |
| work_keys_str_mv | AT nikitaermolaev potentialhematopoieticeffectsofsglt2inhibitorsinpatientswithcardiacamyloidosis AT robinwillixhofer potentialhematopoieticeffectsofsglt2inhibitorsinpatientswithcardiacamyloidosis AT christophkrall potentialhematopoieticeffectsofsglt2inhibitorsinpatientswithcardiacamyloidosis AT christinakronberger potentialhematopoieticeffectsofsglt2inhibitorsinpatientswithcardiacamyloidosis AT renerettl potentialhematopoieticeffectsofsglt2inhibitorsinpatientswithcardiacamyloidosis AT christinabinder potentialhematopoieticeffectsofsglt2inhibitorsinpatientswithcardiacamyloidosis AT franzduca potentialhematopoieticeffectsofsglt2inhibitorsinpatientswithcardiacamyloidosis AT christiannitsche potentialhematopoieticeffectsofsglt2inhibitorsinpatientswithcardiacamyloidosis AT andreaskammerlander potentialhematopoieticeffectsofsglt2inhibitorsinpatientswithcardiacamyloidosis AT michaelpoledniczek potentialhematopoieticeffectsofsglt2inhibitorsinpatientswithcardiacamyloidosis AT bernhardgregshammer potentialhematopoieticeffectsofsglt2inhibitorsinpatientswithcardiacamyloidosis AT dianaahmadifazel potentialhematopoieticeffectsofsglt2inhibitorsinpatientswithcardiacamyloidosis AT mahshideslami potentialhematopoieticeffectsofsglt2inhibitorsinpatientswithcardiacamyloidosis AT lucianacamuzligios potentialhematopoieticeffectsofsglt2inhibitorsinpatientswithcardiacamyloidosis AT johanneskastner potentialhematopoieticeffectsofsglt2inhibitorsinpatientswithcardiacamyloidosis AT juttaberglerklein potentialhematopoieticeffectsofsglt2inhibitorsinpatientswithcardiacamyloidosis AT rozabadreslam potentialhematopoieticeffectsofsglt2inhibitorsinpatientswithcardiacamyloidosis |